Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor

Hyung Chun Park, Yoo Shik Shim, Yoon Ha, Seung Hwan Yoon, So Ra Park, Byung Hyune Choi, Hyun Seon Park

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Transplantation of bone marrow cells into the injured spinal cord has been found to improve neurologic functions in experimental animal studies. However, it is unclear whether bone marrow cells can similarly improve the neurologic functions of complete spinal cord injury (SCI) in human patients. To address this issue, we evaluated the therapeutic effects of autologous bone marrow cell transplantation (BMT) in conjunction with the administration of granulocyte macrophage-colony stimulating factor (GM-CSF) in six complete SCI patients. BMT in the injury site (1.1 × 106 cells/μL in a total of 1.8 mL) and subcutaneous GM-CSF administration were performed on five patients. One patient was treated with GM-CSF only. The follow-up periods were from 6 to 18 months, depending on the patients. Sensory improvements were noted immediately after the operations. Sensory recovery in the sacral segment was noted mainly 3 weeks to 7 months postoperatively. Significant motor improvements were noted 3 to 7 months postoperatively. Four patients showed neurologic improvements in their American Spiral Injury Association Impairment Scale (AIS) grades (from A to C). One patient improved to AIS grade B from A and the last patient remained in AIS grade A. No immediate worsening of neurologic symptoms was found. Side effects of GM-CSF treatment such as a fever (>38°C) and myalgia were noted. Serious complications increasing mortality and morbidity were not found. The follow-up study with magnetic resonance imaging 4-6 months after injury showed slight enhancement within the zone of BMT. Syrinx formation was not definitely found. BMT and GM-CSF administration represent a safe protocol to efficiently manage SCI patients, especially those with acute complete injury. To demonstrate the full therapeutic value of this protocol, long-term and more comprehensive case-control clinical studies are required.

Original languageEnglish
Pages (from-to)913-922
Number of pages10
JournalTissue Engineering
Volume11
Issue number5-6
DOIs
Publication statusPublished - 2005 May 1

Fingerprint

Macrophages
Bone
Cells
Syringes
Magnetic resonance
Animals
Imaging techniques
Recovery

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biophysics
  • Cell Biology

Cite this

Park, Hyung Chun ; Shim, Yoo Shik ; Ha, Yoon ; Yoon, Seung Hwan ; Park, So Ra ; Choi, Byung Hyune ; Park, Hyun Seon. / Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. In: Tissue Engineering. 2005 ; Vol. 11, No. 5-6. pp. 913-922.
@article{1cb3a756dae04b99b939c30990bdb573,
title = "Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor",
abstract = "Transplantation of bone marrow cells into the injured spinal cord has been found to improve neurologic functions in experimental animal studies. However, it is unclear whether bone marrow cells can similarly improve the neurologic functions of complete spinal cord injury (SCI) in human patients. To address this issue, we evaluated the therapeutic effects of autologous bone marrow cell transplantation (BMT) in conjunction with the administration of granulocyte macrophage-colony stimulating factor (GM-CSF) in six complete SCI patients. BMT in the injury site (1.1 × 106 cells/μL in a total of 1.8 mL) and subcutaneous GM-CSF administration were performed on five patients. One patient was treated with GM-CSF only. The follow-up periods were from 6 to 18 months, depending on the patients. Sensory improvements were noted immediately after the operations. Sensory recovery in the sacral segment was noted mainly 3 weeks to 7 months postoperatively. Significant motor improvements were noted 3 to 7 months postoperatively. Four patients showed neurologic improvements in their American Spiral Injury Association Impairment Scale (AIS) grades (from A to C). One patient improved to AIS grade B from A and the last patient remained in AIS grade A. No immediate worsening of neurologic symptoms was found. Side effects of GM-CSF treatment such as a fever (>38°C) and myalgia were noted. Serious complications increasing mortality and morbidity were not found. The follow-up study with magnetic resonance imaging 4-6 months after injury showed slight enhancement within the zone of BMT. Syrinx formation was not definitely found. BMT and GM-CSF administration represent a safe protocol to efficiently manage SCI patients, especially those with acute complete injury. To demonstrate the full therapeutic value of this protocol, long-term and more comprehensive case-control clinical studies are required.",
author = "Park, {Hyung Chun} and Shim, {Yoo Shik} and Yoon Ha and Yoon, {Seung Hwan} and Park, {So Ra} and Choi, {Byung Hyune} and Park, {Hyun Seon}",
year = "2005",
month = "5",
day = "1",
doi = "10.1089/ten.2005.11.913",
language = "English",
volume = "11",
pages = "913--922",
journal = "Tissue Engineering",
issn = "1076-3279",
publisher = "Mary Ann Liebert Inc.",
number = "5-6",

}

Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor. / Park, Hyung Chun; Shim, Yoo Shik; Ha, Yoon; Yoon, Seung Hwan; Park, So Ra; Choi, Byung Hyune; Park, Hyun Seon.

In: Tissue Engineering, Vol. 11, No. 5-6, 01.05.2005, p. 913-922.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of complete spinal cord injury patients by autologous bone marrow cell transplantation and administration of granulocyte-macrophage colony stimulating factor

AU - Park, Hyung Chun

AU - Shim, Yoo Shik

AU - Ha, Yoon

AU - Yoon, Seung Hwan

AU - Park, So Ra

AU - Choi, Byung Hyune

AU - Park, Hyun Seon

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Transplantation of bone marrow cells into the injured spinal cord has been found to improve neurologic functions in experimental animal studies. However, it is unclear whether bone marrow cells can similarly improve the neurologic functions of complete spinal cord injury (SCI) in human patients. To address this issue, we evaluated the therapeutic effects of autologous bone marrow cell transplantation (BMT) in conjunction with the administration of granulocyte macrophage-colony stimulating factor (GM-CSF) in six complete SCI patients. BMT in the injury site (1.1 × 106 cells/μL in a total of 1.8 mL) and subcutaneous GM-CSF administration were performed on five patients. One patient was treated with GM-CSF only. The follow-up periods were from 6 to 18 months, depending on the patients. Sensory improvements were noted immediately after the operations. Sensory recovery in the sacral segment was noted mainly 3 weeks to 7 months postoperatively. Significant motor improvements were noted 3 to 7 months postoperatively. Four patients showed neurologic improvements in their American Spiral Injury Association Impairment Scale (AIS) grades (from A to C). One patient improved to AIS grade B from A and the last patient remained in AIS grade A. No immediate worsening of neurologic symptoms was found. Side effects of GM-CSF treatment such as a fever (>38°C) and myalgia were noted. Serious complications increasing mortality and morbidity were not found. The follow-up study with magnetic resonance imaging 4-6 months after injury showed slight enhancement within the zone of BMT. Syrinx formation was not definitely found. BMT and GM-CSF administration represent a safe protocol to efficiently manage SCI patients, especially those with acute complete injury. To demonstrate the full therapeutic value of this protocol, long-term and more comprehensive case-control clinical studies are required.

AB - Transplantation of bone marrow cells into the injured spinal cord has been found to improve neurologic functions in experimental animal studies. However, it is unclear whether bone marrow cells can similarly improve the neurologic functions of complete spinal cord injury (SCI) in human patients. To address this issue, we evaluated the therapeutic effects of autologous bone marrow cell transplantation (BMT) in conjunction with the administration of granulocyte macrophage-colony stimulating factor (GM-CSF) in six complete SCI patients. BMT in the injury site (1.1 × 106 cells/μL in a total of 1.8 mL) and subcutaneous GM-CSF administration were performed on five patients. One patient was treated with GM-CSF only. The follow-up periods were from 6 to 18 months, depending on the patients. Sensory improvements were noted immediately after the operations. Sensory recovery in the sacral segment was noted mainly 3 weeks to 7 months postoperatively. Significant motor improvements were noted 3 to 7 months postoperatively. Four patients showed neurologic improvements in their American Spiral Injury Association Impairment Scale (AIS) grades (from A to C). One patient improved to AIS grade B from A and the last patient remained in AIS grade A. No immediate worsening of neurologic symptoms was found. Side effects of GM-CSF treatment such as a fever (>38°C) and myalgia were noted. Serious complications increasing mortality and morbidity were not found. The follow-up study with magnetic resonance imaging 4-6 months after injury showed slight enhancement within the zone of BMT. Syrinx formation was not definitely found. BMT and GM-CSF administration represent a safe protocol to efficiently manage SCI patients, especially those with acute complete injury. To demonstrate the full therapeutic value of this protocol, long-term and more comprehensive case-control clinical studies are required.

UR - http://www.scopus.com/inward/record.url?scp=21844442589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21844442589&partnerID=8YFLogxK

U2 - 10.1089/ten.2005.11.913

DO - 10.1089/ten.2005.11.913

M3 - Article

C2 - 15998231

AN - SCOPUS:21844442589

VL - 11

SP - 913

EP - 922

JO - Tissue Engineering

JF - Tissue Engineering

SN - 1076-3279

IS - 5-6

ER -